Successful treatment with vemurafenib in BRAF V600K-positive cerebral melanoma metastasis

JAMA Dermatology

Volumn 149, Issue 5, 2013, Pages 642-644

  Forschner, Andrea ^a   Niessner, Heike ^a   Bauer, Juergen ^a   Bender, Benjamin ^a   Garbe, Claus ^a   Meier, Friedegund ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; VEMURAFENIB;

ADULT; ARTICLE; BRAIN CANCER; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; LUNG CANCER; MELANOMA METASTASIS; MUTATIONAL ANALYSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SKIN CANCER;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; FEMALE; HUMANS; INDOLES; MAGNETIC RESONANCE IMAGING; MELANOMA; MIDDLE AGED; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84877862505     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.372     Document Type: Article

References (5)

1. Spittle C, Ward MR, Nathanson KL, et al. Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn. 2007;9(4):464-471. (Pubitemid 47434113)
2. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
3. Dummer R, Rinderknecht J, Goldinger SM, et al. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. J Clin Oncol. 2011;29(suppl):abstract 8548.
4. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379(9829):1893-1901.
5. Kirkwood JM, Long GV, Trefzer U, et al. BREAK-MB: A phase II study assessing overall intracranial response rate to dabrafenib (GSK2118436) in patients with BRAF V600E/K mutation-positive melanoma with brain metastases. J Clin Oncol. 2012;30(suppl):abstract 8501.